Similar articles for PMID: 8195882

Year	Number of Results
1986	1
1989	1
1990	3
1991	6
1992	7
1993	9
1994	7
1995	6
1996	8
1997	11
1998	2
1999	5
2000	4
2001	3
2002	2
2003	2
2004	4
2005	4
2006	3
2009	2
2011	3
2013	1
2014	1
2016	2
2017	2
2019	1
2021	1
2022	1
2024	0

1

Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.

Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, Mandel F, Spetsieris P, Eidelberg D. Takikawa S, et al. J Nucl Med. 1994 Jun;35(6):955-63. J Nucl Med. 1994. PMID: 8195882 Free article.

2

Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.

Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, Mandel F, Spetsieris P, Eidelberg D. Ishikawa T, et al. J Nucl Med. 1996 Feb;37(2):216-22. J Nucl Med. 1996. PMID: 8667047 Free article.

3

Combined FDOPA and 3OMFD PET studies in Parkinson's disease.

Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhlef A, Margouleff C, Mandel F, Eidelberg D. Dhawan V, et al. J Nucl Med. 1996 Feb;37(2):209-16. J Nucl Med. 1996. PMID: 8667046 Free article.

4

Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.

Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D. Ishikawa T, et al. J Cereb Blood Flow Metab. 1996 Sep;16(5):854-63. doi: 10.1097/00004647-199609000-00010. J Cereb Blood Flow Metab. 1996. PMID: 8784230

5

Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.

Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Jokinen P, et al. J Nucl Med. 2009 Jun;50(6):893-9. doi: 10.2967/jnumed.108.061572. Epub 2009 May 14. J Nucl Med. 2009. PMID: 19443601 Free article.

6

Striatal 18F-dopa uptake: absence of an aging effect.

Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Moeller JR, Patlak CS, Fahn S. Eidelberg D, et al. J Cereb Blood Flow Metab. 1993 Sep;13(5):881-8. doi: 10.1038/jcbfm.1993.110. J Cereb Blood Flow Metab. 1993. PMID: 8360294

7

Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach.

Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, Margouleff C, Eidelberg D. Dhawan V, et al. J Nucl Med. 2002 Oct;43(10):1324-30. J Nucl Med. 2002. PMID: 12368370 Free article.

8

Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition.

Psylla M, Günther I, Antonini A, Vontobel P, Reist HW, Zollinger A, Leenders KL. Psylla M, et al. Brain Res. 1997 Aug 29;767(1):45-54. doi: 10.1016/s0006-8993(97)00552-0. Brain Res. 1997. PMID: 9365014

9

The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.

Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA. Eidelberg D, et al. Mov Disord. 1990;5(3):203-13. doi: 10.1002/mds.870050304. Mov Disord. 1990. PMID: 2117706

10

Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.

Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK. Ruottinen HM, et al. Synapse. 1997 Dec;27(4):336-46. doi: 10.1002/(SICI)1098-2396(199712)27:4<336::AID-SYN7>3.0.CO;2-D. Synapse. 1997. PMID: 9372556

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year